AtriCure, Inc. (A5I.F)

62,00 0,00 (0,00%) Börsenschluss: 01:45PM CEST

AtriCure, Inc.

7555 Innovation Way
Mason, OH 45040
United States
513 755 4100
https://www.atricure.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 1.200

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Michael H. Carrel	CEO, President & Director	1,87M	N/A	1971
Ms. Angela L. Wirick CPA	Chief Financial Officer	784,46k	N/A	1978
Mr. Douglas J. Seith	Chief Operating Officer	1,12M	N/A	1966
Mr. Salvatore Privitera J.D.	Chief Technical Officer	707,34k	N/A	1967
Mr. Karl S. Dahlquist CCEP, J.D.	Chief Legal Officer	710,68k	N/A	1971
Dr. Vinayak Doraiswamy Ph.D.	Chief Scientific Officer	724,91k	N/A	1972
Valerie Storch-Willhaus	Vice President of Corporate Marketing & Communications	N/A	N/A	N/A
Mr. Justin J. Noznesky	Chief Marketing & Strategy Officer	601k	N/A	1978
Ms. Deborah Yount	Chief Human Resources Officer	464,56k	N/A	1966

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Corporate Governance

AtriCure, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 2. Die grundlegenden Scores sind Audit: 5, Vorstand: 1, Shareholderrechte: 3, Kompensation: 3.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.